MX2022005994A - Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras. - Google Patents
Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.Info
- Publication number
- MX2022005994A MX2022005994A MX2022005994A MX2022005994A MX2022005994A MX 2022005994 A MX2022005994 A MX 2022005994A MX 2022005994 A MX2022005994 A MX 2022005994A MX 2022005994 A MX2022005994 A MX 2022005994A MX 2022005994 A MX2022005994 A MX 2022005994A
- Authority
- MX
- Mexico
- Prior art keywords
- fak inhibitor
- treating tumors
- nras mutation
- drug
- preparation
- Prior art date
Links
- 229940124783 FAK inhibitor Drugs 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 230000035772 mutation Effects 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 101150073096 NRAS gene Proteins 0.000 title 1
- 102100039788 GTPase NRas Human genes 0.000 abstract 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 abstract 3
- IGUBBWJDMLCRIK-UHFFFAOYSA-N 2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=CC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1C(F)(F)F IGUBBWJDMLCRIK-UHFFFAOYSA-N 0.000 abstract 1
- BVAHPPKGOOJSPU-UHFFFAOYSA-N 2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC=C1NC1=CC(NC=2N(N=C(C)C=2)C(C)C)=NC=C1Cl BVAHPPKGOOJSPU-UHFFFAOYSA-N 0.000 abstract 1
- ULMMVBPTWVRPSI-UHFFFAOYSA-N 2-fluoro-5-methoxy-4-[[4-[(2-methyl-3-oxo-1h-isoindol-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-n-(1-methylpiperidin-4-yl)benzamide Chemical group FC=1C=C(NC=2N=C(OC=3C=4C(=O)N(C)CC=4C=CC=3)C(=CN=2)C(F)(F)F)C(OC)=CC=1C(=O)NC1CCN(C)CC1 ULMMVBPTWVRPSI-UHFFFAOYSA-N 0.000 abstract 1
- LKLWTLXTOVZFAE-UHFFFAOYSA-N benzenesulfonic acid;n-methyl-n-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.CS(=O)(=O)N(C)C1=NC=CC=C1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F LKLWTLXTOVZFAE-UHFFFAOYSA-N 0.000 abstract 1
- 229950008937 defactinib Drugs 0.000 abstract 1
- FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un uso de un inhibidor de FAK en la preparación de un fármaco para prevenir y/o tratar tumores que tengan una mutación de NRAS. Un método para el tratamiento contra tumores que han experimentado una mutación de NRAS, que comprende que le sea administrable una dosis eficaz de un inhibidor de FAK a un individuo. Un inhibidor de FAK para el tratamiento contra tumores que tienen una mutación de NRAS. El inhibidor de FAK es BI853520, defactinib, GSK2256098, PF-00562271, VS-4718 o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911128794 | 2019-11-18 | ||
| PCT/CN2020/129350 WO2021098679A1 (zh) | 2019-11-18 | 2020-11-17 | Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005994A true MX2022005994A (es) | 2022-06-17 |
Family
ID=75981319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005994A MX2022005994A (es) | 2019-11-18 | 2020-11-17 | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230145356A1 (es) |
| EP (1) | EP4062914A4 (es) |
| JP (1) | JP2023503897A (es) |
| KR (1) | KR20220101677A (es) |
| CN (1) | CN114667144A (es) |
| AU (1) | AU2020388848A1 (es) |
| BR (1) | BR112022009571A2 (es) |
| CA (1) | CA3158585A1 (es) |
| MX (1) | MX2022005994A (es) |
| PE (1) | PE20221259A1 (es) |
| WO (1) | WO2021098679A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114728005A (zh) * | 2019-11-28 | 2022-07-08 | 应世生物科技(南京)有限公司 | Bi853520在癌症治疗中的用途 |
| JP2023515765A (ja) * | 2020-02-05 | 2023-04-14 | ▲應▼世生物科技（南京）有限公司 | Ｂｉ８５３５２０と化学療法薬の併用 |
| BR112023001962A2 (pt) * | 2020-08-03 | 2023-04-11 | Inxmed Nanjing Co Ltd | Forma sólida de composto |
| CN113855695B (zh) * | 2021-11-01 | 2023-06-06 | 上海理工大学 | 一种结肠释药口服复方药物组合物及其制备方法 |
| TW202339755A (zh) * | 2021-12-10 | 2023-10-16 | 大陸商應世生物科技（南京）有限公司 | 治療腫瘤的藥物組合及用途 |
| CN114681471B (zh) * | 2022-01-19 | 2023-06-06 | 杭州师范大学 | 一种硼替佐米和榄香烯分子配伍药物组合及其应用 |
| WO2023138630A1 (zh) * | 2022-01-21 | 2023-07-27 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| CN116889565A (zh) * | 2022-04-07 | 2023-10-17 | 深圳微芯生物科技股份有限公司 | 西奥罗尼在抗胰腺癌中的用途 |
| TW202408528A (zh) | 2022-06-24 | 2024-03-01 | 大陸商應世生物科技（南京）有限公司 | 治療腫瘤的藥物組合及用途 |
| CN117582504A (zh) * | 2022-08-15 | 2024-02-23 | 海创药业股份有限公司 | 一种治疗卵巢癌的联合用药物 |
| WO2024041527A1 (zh) * | 2022-08-24 | 2024-02-29 | 应世生物科技(南京)有限公司 | Fak抑制剂及微管抑制剂的药物组合及用途 |
| TW202410898A (zh) * | 2022-09-05 | 2024-03-16 | 大陸商應世生物科技（南京）有限公司 | Fak抑制劑及egfr-tki的藥物組合及用途 |
| WO2024067631A1 (zh) * | 2022-09-30 | 2024-04-04 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI491605B (zh) * | 2008-11-24 | 2015-07-11 | Boehringer Ingelheim Int | 新穎化合物 |
| ES2945387T3 (es) * | 2014-02-07 | 2023-06-30 | Verastem Inc | Procedimientos y composiciones para tratar el crecimiento celular anormal |
| KR20180100539A (ko) * | 2015-06-29 | 2018-09-11 | 베라스템, 인코포레이티드 | 치료용 조성물, 병용 및 적용과 관련된 사용방법 |
| JP2022547358A (ja) * | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
| JP2023515765A (ja) * | 2020-02-05 | 2023-04-14 | ▲應▼世生物科技（南京）有限公司 | Ｂｉ８５３５２０と化学療法薬の併用 |
-
2020
- 2020-11-17 KR KR1020227020144A patent/KR20220101677A/ko active Search and Examination
- 2020-11-17 JP JP2022529446A patent/JP2023503897A/ja active Pending
- 2020-11-17 WO PCT/CN2020/129350 patent/WO2021098679A1/zh unknown
- 2020-11-17 EP EP20890277.5A patent/EP4062914A4/en active Pending
- 2020-11-17 US US17/777,769 patent/US20230145356A1/en active Pending
- 2020-11-17 PE PE2022000810A patent/PE20221259A1/es unknown
- 2020-11-17 BR BR112022009571A patent/BR112022009571A2/pt unknown
- 2020-11-17 AU AU2020388848A patent/AU2020388848A1/en active Pending
- 2020-11-17 MX MX2022005994A patent/MX2022005994A/es unknown
- 2020-11-17 CA CA3158585A patent/CA3158585A1/en active Pending
- 2020-11-17 CN CN202080078892.0A patent/CN114667144A/zh active Pending
-
2023
- 2023-07-11 US US18/350,303 patent/US20230364088A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3158585A1 (en) | 2021-05-27 |
| EP4062914A4 (en) | 2024-01-17 |
| WO2021098679A1 (zh) | 2021-05-27 |
| KR20220101677A (ko) | 2022-07-19 |
| BR112022009571A2 (pt) | 2022-08-02 |
| EP4062914A1 (en) | 2022-09-28 |
| US20230364088A1 (en) | 2023-11-16 |
| US20230145356A1 (en) | 2023-05-11 |
| JP2023503897A (ja) | 2023-02-01 |
| CN114667144A (zh) | 2022-06-24 |
| PE20221259A1 (es) | 2022-08-16 |
| AU2020388848A1 (en) | 2022-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005994A (es) | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2022012285A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). | |
| MX2021008247A (es) | Combinacion de dextrometorfano y bupropion para el tratamiento de depresion. | |
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX2019003733A (es) | Tratamiento de cancer de prostata. | |
| MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
| MX2022000143A (es) | Metodos novedosos. | |
| MX2022008490A (es) | Metodos de tratamiento de la esplenomegalia. | |
| MX2021002322A (es) | Nuevos metodos. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
| MX2020007404A (es) | Metodos y terapia de combincion para tratar cancer. | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| BR112017024073A2 (pt) | métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinase | |
| EA202193211A1 (ru) | Лечение синуклеопатий | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. |